Trials / Completed
CompletedNCT00624286
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 416 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indacaterol 150 μg | Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. |
| DRUG | Placebo to indacaterol | Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2008-02-27
- Last updated
- 2011-08-18
- Results posted
- 2011-08-18
Locations
120 sites across 3 countries: United States, Belgium, New Zealand
Source: ClinicalTrials.gov record NCT00624286. Inclusion in this directory is not an endorsement.